Exkivity, an anti-cancer drug targeting EGFR exon 20 insertion mutation, is aiming for insurance coverage. Takeda Korea recently submitted a reimbursement application for Exkivity, a treatment for non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation. This drug targets the same biomarker as Janssen's Rybrevant but differs in that it is an oral drug. EGFR Exon 20 insertion mutation is a new biomarker that has recently attracted attention in the field of non-small cell lung cancer. Currently available anticancer drugs are suitable for Exon19 deletion or Exon21 L858R substitution mutation, which are commonly found in EGFR mutations, but EGFR Exon20 was still a blind spot. Accordingly, it remains to b